213 related articles for article (PubMed ID: 35747403)
21. Role of the Transcription Factor Yin Yang 1 and Its Selectively Identified Target Survivin in High-Grade B-Cells Non-Hodgkin Lymphomas: Potential Diagnostic and Therapeutic Targets.
Vivarelli S; Falzone L; Ligresti G; Candido S; Garozzo A; Magro GG; Bonavida B; Libra M
Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32899428
[TBL] [Abstract][Full Text] [Related]
22. Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens.
Carey CD; Gusenleitner D; Chapuy B; Kovach AE; Kluk MJ; Sun HH; Crossland RE; Bacon CM; Rand V; Dal Cin P; Le LP; Neuberg D; Sohani AR; Shipp MA; Monti S; Rodig SJ
J Mol Diagn; 2015 Jan; 17(1):19-30. PubMed ID: 25468432
[TBL] [Abstract][Full Text] [Related]
23. 3D-culture models as drug-testing platforms in canine lymphoma and their cross talk with lymph node-derived stromal cells.
An JH; Song WJ; Li Q; Bhang DH; Youn HY
J Vet Sci; 2021 May; 22(3):e25. PubMed ID: 33908202
[TBL] [Abstract][Full Text] [Related]
24. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
25. A bone-based 3D scaffold as an
Ceccato J; Piazza M; Pizzi M; Manni S; Piazza F; Caputo I; Cinetto F; Pisoni L; Trojan D; Scarpa R; Zambello R; Tos APD; Trentin L; Semenzato G; Vianello F
Front Oncol; 2022; 12():947823. PubMed ID: 36330473
[TBL] [Abstract][Full Text] [Related]
26. Hybrid collagen alginate hydrogel as a platform for 3D tumor spheroid invasion.
Liu C; Lewin Mejia D; Chiang B; Luker KE; Luker GD
Acta Biomater; 2018 Jul; 75():213-225. PubMed ID: 29879553
[TBL] [Abstract][Full Text] [Related]
27. [Non-hodgkin's lymphomas].
Drouet F; Cahu X; Pointreau Y; Denis F; Mahé MA
Cancer Radiother; 2010 Nov; 14 Suppl 1():S210-29. PubMed ID: 21129666
[TBL] [Abstract][Full Text] [Related]
28. Differential expression of WT1 gene product in non-Hodgkin lymphomas.
Drakos E; Rassidakis GZ; Tsioli P; Lai R; Jones D; Medeiros LJ
Appl Immunohistochem Mol Morphol; 2005 Jun; 13(2):132-7. PubMed ID: 15894924
[TBL] [Abstract][Full Text] [Related]
29. Novel Therapies Potentially Available for Pediatric B-Cell Non-Hodgkin Lymphoma.
Harker-Murray PD; Pommert L; Barth MJ
J Natl Compr Canc Netw; 2020 Aug; 18(8):1125-1134. PubMed ID: 32755987
[TBL] [Abstract][Full Text] [Related]
30. Changes in the secretome of tri-dimensional spheroid-cultured human mesenchymal stem cells in vitro by interleukin-1 priming.
Redondo-Castro E; Cunningham CJ; Miller J; Brown H; Allan SM; Pinteaux E
Stem Cell Res Ther; 2018 Jan; 9(1):11. PubMed ID: 29343288
[TBL] [Abstract][Full Text] [Related]
31. Stiffness-Controlled Hydrogels for 3D Cell Culture Models.
Merivaara A; Koivunotko E; Manninen K; Kaseva T; Monola J; Salli E; Koivuniemi R; Savolainen S; Valkonen S; Yliperttula M
Polymers (Basel); 2022 Dec; 14(24):. PubMed ID: 36559897
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of the GMALL-B-ALL/NHL2002 protocol in Burkitt leukemia/lymphoma and aggressive non-Hodgkin-lymphomas with or without CNS involvement.
Sakarou M; Eisele L; Dührsen U; Hüttmann A
Eur J Haematol; 2019 Mar; 102(3):241-250. PubMed ID: 30471148
[TBL] [Abstract][Full Text] [Related]
33. Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system?
Bladergroen BA; Meijer CJ; ten Berge RL; Hack CE; Muris JJ; Dukers DF; Chott A; Kazama Y; Oudejans JJ; van Berkum O; Kummer JA
Blood; 2002 Jan; 99(1):232-7. PubMed ID: 11756176
[TBL] [Abstract][Full Text] [Related]
34. Overview of rational and individualized therapeutic strategies for non-Hodgkin's lymphomas.
Armitage JO
Clin Lymphoma; 2002 Dec; 3 Suppl 1():S5-11. PubMed ID: 12521383
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA signatures in B-cell lymphomas.
Di Lisio L; Sánchez-Beato M; Gómez-López G; Rodríguez ME; Montes-Moreno S; Mollejo M; Menárguez J; Martínez MA; Alves FJ; Pisano DG; Piris MA; Martínez N
Blood Cancer J; 2012 Feb; 2(2):e57. PubMed ID: 22829247
[TBL] [Abstract][Full Text] [Related]
36. Bioengineering a humanized 3D tri-culture osteosarcoma model to assess tumor invasiveness and therapy response.
Monteiro CF; Custódio CA; Mano JF
Acta Biomater; 2021 Oct; 134():204-214. PubMed ID: 34303015
[TBL] [Abstract][Full Text] [Related]
37. A Shaking-Culture Method for Generating Bone Marrow Derived Mesenchymal Stromal/Stem Cell-Spheroids With Enhanced Multipotency
Niibe K; Ohori-Morita Y; Zhang M; Mabuchi Y; Matsuzaki Y; Egusa H
Front Bioeng Biotechnol; 2020; 8():590332. PubMed ID: 33195156
[TBL] [Abstract][Full Text] [Related]
38. Paraffin-resistant antigens detectable by antibodies L26 and polyclonal CD3 predict the B- or T-cell lineage of 95% of diffuse aggressive non-Hodgkin's lymphomas.
Chadburn A; Knowles DM
Am J Clin Pathol; 1994 Sep; 102(3):284-91. PubMed ID: 8085550
[TBL] [Abstract][Full Text] [Related]
39. Epstein-Barr virus is infrequently identified in non-Hodgkin's lymphomas associated with Hodgkin's disease.
Kingma DW; Medeiros LJ; Barletta J; Raffeld M; Mann RB; Ambinder RF; Jaffe ES
Am J Surg Pathol; 1994 Jan; 18(1):48-61. PubMed ID: 8279628
[TBL] [Abstract][Full Text] [Related]
40. Unusual presentation of diffuse large B-cell non-Hodgkin's lymphoma in children: bilateral ureteral involvement.
Kantar M; Hekimgil M; Harman M; Oral A; Öge Ö; Avanoglu A
Pediatr Hematol Oncol; 2019 Nov; 36(8):504-509. PubMed ID: 31566047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
